Clinical Trial Update: Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing ketorolac 0.4% versus bromfenac 0.09% in cataract patients measured trough aqueous concentrations and PGE2 inhibition; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• BROMFENAC (Bromfenac)
• Ketorolac (Ketorolac tromethamine)

Snippet

Sponsor: Innovative Medical | Conditions: Cataract | Phase 4 | Status: COMPLETED